Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heron's Sustol Faces Competition With Narrower Label Than Expected

Executive Summary

Heron Therapeutics gained approval of its chemotherapy-induced nausea and vomiting drug Sustol (granisetron), but the company faces stiff competition and postmarketing requirements. Analysts, nonetheless, think the product has a bright future on the US market.

You may also be interested in...

Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash

Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.

Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

The latest drug development news and highlights from our FDA Performance Tracker.

Heron hammered over Sustol NDA resubmission delay

Investors hammered Heron Therapeutics on 27 January, with shares tumbling as low as 19.2% in morning trading, after the company revealed it was forced to delay by at least three months its resubmission to the FDA of the firm’s new drug application (NDA) for its experimental chemotherapy-induced nausea and vomiting (CINV) drug Sustol (APF530).

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts